journal
MENU ▼
Read by QxMD icon Read
search

Cancer

journal
https://www.readbyqxmd.com/read/28544601/the-impact-of-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-on-the-performance-of-the-afirma-gene-expression-classifier
#1
Jen-Fan Hang, William H Westra, David S Cooper, Syed Z Ali
BACKGROUND: A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC). METHODS: The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed...
May 24, 2017: Cancer
https://www.readbyqxmd.com/read/28543182/prognostic-significance-of-promoter-cpg-island-methylation-of-obesity-related-genes-in-patients-with-nonmetastatic-renal-cell-carcinoma
#2
Julia Mendoza-Pérez, Jian Gu, Luis A Herrera, Nizar M Tannir, Shanyu Zhang, Surena Matin, Jose A Karam, Christopher G Wood, Xifeng Wu
BACKGROUND: Greater than 40% of renal cell carcinoma (RCC) cases in the United States are attributed to excessive body weight. Moreover, obesity also may be linked to RCC prognosis. However, the molecular mechanisms underlying these associations are unclear. In the current study, the authors evaluated the role of promoter methylation in obesity-related genes in RCC tumorigenesis and disease recurrence. METHODS: Paired tumors (TU) and normal adjacent (N-Adj) tissues from 240 newly diagnosed and previously untreated white patients with RCC were examined...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542918/multisite-external-validation-of-a-risk-prediction-model-for-the-diagnosis-of-blood-stream-infections-in-febrile-pediatric-oncology-patients-without-severe-neutropenia
#3
Adam J Esbenshade, Zhiguo Zhao, Catherine Aftandilian, Raya Saab, Rachel L Wattier, Melissa Beauchemin, Tamara P Miller, Jennifer J Wilkes, Michael J Kelly, Alison Fernbach, Michael Jeng, Cindy L Schwartz, Christopher C Dvorak, Yu Shyr, Karl G M Moons, Maria-Luisa Sulis, Debra L Friedman
BACKGROUND: Pediatric oncology patients are at an increased risk of invasive bacterial infection due to immunosuppression. The risk of such infection in the absence of severe neutropenia (absolute neutrophil count ≥ 500/μL) is not well established and a validated prediction model for blood stream infection (BSI) risk offers clinical usefulness. METHODS: A 6-site retrospective external validation was conducted using a previously published risk prediction model for BSI in febrile pediatric oncology patients without severe neutropenia: the Esbenshade/Vanderbilt (EsVan) model...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542870/the-breast-and-cervical-cancer-early-detection-program-medicaid-and-breast-cancer-outcomes-among-ohio-s-underserved-women
#4
Siran M Koroukian, Paul M Bakaki, Phyo Than Htoo, Xiaozhen Han, Mark Schluchter, Cynthia Owusu, Gregory S Cooper, Johnie Rose, Susan A Flocke
BACKGROUND: As an organized screening program, the national Breast and Cervical Cancer Early Detection Program (BCCEDP) was launched in the early 1990s to improve breast cancer outcomes among underserved women. To analyze the impact of the BCCEDP on breast cancer outcomes in Ohio, this study compared cancer stages and mortality across BCCEDP participants, Medicaid beneficiaries, and "all others." METHODS: This study linked data across the Ohio Cancer Incidence Surveillance System, Medicaid, the BCCEDP database, death certificates, and the US Census and identified 26,426 women aged 40 to 64 years who had been diagnosed with incident invasive breast cancer during the years 2002-2008 (deaths through 2010)...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542843/next-generation-sequencing-of-a-family-with-a-high-penetrance-of-monoclonal-gammopathies-for-the-identification-of-candidate-risk-alleles
#5
Niccolo Bolli, Matteo Barcella, Erika Salvi, Francesca D'Avila, Antonio Vendramin, Chiara De Philippis, Nikhil C Munshi, Herve Avet-Loiseau, Peter J Campbell, Alberto Mussetti, Cristiana Carniti, Francesco Maura, Cristina Barlassina, Paolo Corradini, Vittorio Montefusco
BACKGROUND: The authors describe a family with a high penetrance of plasma cell dyscrasias, suggesting inheritance of an autosomal dominant risk allele. METHODS: The authors performed whole-exome sequencing and reported on a combined approach aimed at the identification of causative variants and risk loci, using the wealth of data provided by this approach. RESULTS: The authors identified gene mutations and single-nucleotide polymorphisms of potential significance, and pinpointed a known risk locus for myeloma as a potential area of transmissible risk in the family...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542736/understanding-temporal-trends-in-medical-costs-associated-with-progression-to-metastatic-prostate-cancer
#6
Daniel M Frendl, Aria F Olumi
No abstract text is available yet for this article.
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542734/cost-related-medication-nonadherence-among-adolescent-and-young-adult-cancer-survivors
#7
Sapna Kaul, Jaqueline C Avila, Hemalkumar B Mehta, Ana M Rodriguez, Yong-Fang Kuo, Anne C Kirchhoff
BACKGROUND: This study investigated cost-related medication nonadherence among survivors of adolescent and young adult cancer and a comparison group in the United States. METHODS: A cross-sectional analysis of the 2013 to 2015 National Health Interview Survey was performed. N=953 patients who were diagnosed with cancer between the ages of 15 and 39 years were identified, and a comparison group was created using propensity scores. Cost-related medication nonadherence was determined by individuals' report of skipping medication, taking less medication, or delaying filling medication to save money in the previous year...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542732/impact-of-subsequent-metastases-on-costs-and-medical-resource-use-for-prostate-cancer-patients-initially-diagnosed-with-localized-disease
#8
Tracy T Li, Neal D Shore, Maneesha Mehra, Mary B Todd, Ryan Saadi, Gaetan Leblay, Jyoti Aggarwal, Robert I Griffiths
BACKGROUND: The impact of subsequent metastases on costs and medical resource use (MRU) for prostate cancer (PC) patients initially diagnosed with localized disease was estimated. METHODS: Surveillance, Epidemiology, and End Results data, linked to Medicare (1999-2012), were used to identify 7482 patients diagnosed with subsequent metastases 12 months or more after the initial diagnosis of localized PC (cases), and they were matched to 25,709 localized PC patients without subsequent metastases (controls)...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28542721/high-dose-chemotherapy-with-thiotepa-busulfan-and-cyclophosphamide-and-autologous-stem-cell-transplantation-for-pediatric-primary-central-nervous-system-lymphoma-in-first-complete-remission
#9
LETTER
https://www.readbyqxmd.com/read/28542833/why-are-patients-with-blood-cancers-more-likely-to-die-without-hospice
#10
Oreofe O Odejide, Angel M Cronin, Craig C Earle, James A Tulsky, Gregory A Abel
BACKGROUND: Although patients with blood cancers have significantly lower rates of hospice use than those with solid malignancies, data explaining this gap in end-of-life care are sparse. METHODS: In 2015, we conducted a mailed survey of a randomly selected sample of hematologic oncologists in the United States to characterize their perspectives regarding the utility and adequacy of hospice for blood cancer patients, as well as factors that might impact referral patterns...
May 22, 2017: Cancer
https://www.readbyqxmd.com/read/28518284/molecular-profiling-as-a-novel-tool-to-predict-response-to-interferon-%C3%AE-2-in-mpns-the-proof-of-concept-in-early-myelofibrosis
#11
EDITORIAL
Hans Carl Hasselbalch
No abstract text is available yet for this article.
May 18, 2017: Cancer
https://www.readbyqxmd.com/read/28518222/the-effect-of-initial-molecular-profile-on-response-to-recombinant-interferon-%C3%AE-rifn%C3%AE-treatment-in-early-myelofibrosis
#12
Richard T Silver, Ariella C Barel, Elena Lascu, Ellen K Ritchie, Gail J Roboz, Paul J Christos, Attilio Orazi, Duane C Hassane, Wayne Tam, Nicholas C P Cross
BACKGROUND: Although recombinant interferon-α (rIFNα) effectively treats patients with early myelofibrosis, the effect of driver and high molecular risk (HMR) mutations has not been considered. In this phase 2 study, for the first time, the authors correlate response to rIFNα treatment with driver and HMR mutations. METHODS: Patients were diagnosed using World Health Organization or International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria...
May 18, 2017: Cancer
https://www.readbyqxmd.com/read/28518219/impact-of-the-timing-of-hepatitis-b-virus-identification-and-anti-hepatitis-b-virus-therapy-initiation-on-the-risk-of-adverse-liver-outcomes-for-patients-receiving-cancer-therapy
#13
Jessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, Andrea Barbo, Heather Y Lin, Sairah Ahmed, Mariana Chavez-MacGregor, Christian Donato-Santana, Cathy Eng, Alessandra Ferrajoli, Michael J Fisch, Peter McLaughlin, George R Simon, Gabriela Rondon, Elizabeth J Shpall, Anna S Lok
BACKGROUND: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface antigen [HBsAg]-positive/hepatitis B core antibody [anti-HBc]-positive) or past (HBsAg-negative/anti-HBc-positive) hepatitis B virus (HBV) after chemotherapy. This study was aimed at determining the impact of test timing and anti-HBV therapy on adverse liver outcomes in these patients. METHODS: Patients with solid or hematologic malignancies who received chemotherapy between 2004 and 2011 were retrospectively studied...
May 18, 2017: Cancer
https://www.readbyqxmd.com/read/28513834/the-association-between-complications-and-quality-of-life-after-mastectomy-and-breast-reconstruction-for-breast-cancer
#14
John P Browne, Ranjeet Jeevan, Carmel Gulliver-Clarke, Jerome Pereira, Christopher M Caddy, Jan H P van der Meulen
BACKGROUND: Medical treatment for breast cancer is associated with substantial toxicity and patient burden. There is less known about the impact of surgical complications. Understanding this impact could provide important information for patients when they are considering surgical options. METHODS: Between 2008 and 2009, the UK National Mastectomy and Breast Reconstruction Audit recorded surgical complications for a prospective cohort of 17,844 women treated for breast cancer at 270 hospitals; 6405 of these women were surveyed about their quality of life 18 months after surgery...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28513830/association-between-mutations-of-critical-pathway-genes-and-survival-outcomes-according-to-the-tumor-location-in-colorectal-cancer
#15
Dae-Won Lee, Sae-Won Han, Yongjun Cha, Jeong Mo Bae, Hwang-Phill Kim, Jaemyun Lyu, Hyojun Han, Hyoki Kim, Hoon Jang, Duhee Bang, Iksoo Huh, Taesung Park, Jae-Kyung Won, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae-You Kim
BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28513828/outcome-of-autologous-hematopoietic-stem-cell-transplantation-in-refractory-multiple-myeloma
#16
Lauren W Veltri, Denái R Milton, Ruby Delgado, Nina Shah, Krina Patel, Yago Nieto, Partow Kebriaei, Uday R Popat, Simrit Parmar, Betul Oran, Stefan Ciurea, Chitra Hosing, Hans C Lee, Elisabet Manasanch, Robert Z Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash, Qaiser Bashir
BACKGROUND: Despite the introduction of effective, novel agents, the outcome of patients with refractory multiple myeloma remains poor, particularly those who are refractory to both proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). Limited data are available on the role of autologous hematopoietic stem cell transplantation in this population. METHODS: Patients with refractory myeloma who underwent first autologous hematopoietic stem cell transplantation (auto-HCT) between March 2000 and October 2015 were retrospectively analyzed...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28513824/how-we-treat-germ-cell-cancers
#17
Anja Lorch, Jörg Beyer
No abstract text is available yet for this article.
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28513823/adjuvant-radiotherapy-improves-overall-survival-in-patients-with-resected-gastric-adenocarcinoma-a-national-cancer-data-base-analysis
#18
Priscilla K Stumpf, Arya Amini, Bernard L Jones, Matthew Koshy, David J Sher, Christopher H Lieu, Tracey E Schefter, Karyn A Goodman, Chad G Rusthoven
BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28499075/regulatory-considerations-on-endpoints-in-ovarian-cancer-drug-development
#19
REVIEW
Sanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, Richard Pazdur
Ovarian cancer remains a disease entity that is responsible for considerable morbidity and mortality among women worldwide. Modern drug research pipelines and accelerated drug development timelines applied to other disease entities have begun to make an impact on treatment options for patients with advanced ovarian cancer, as exemplified by the recent accelerated approval of 2 agents for this disease as the forerunners of a growing number of registrational trials. Regulatory flexibility for this serious and life-threatening condition spurs the consideration of intermediate endpoints for regulatory trial design, including potential applications in the development of newer therapeutic classes such as targeted therapies and immunotherapies for patients with advanced ovarian cancer...
May 12, 2017: Cancer
https://www.readbyqxmd.com/read/28499074/drug-development-and-registration-challenges-and-opportunities-in-ovarian-cancer
#20
EDITORIAL
S Percy Ivy, Elise C Kohn
No abstract text is available yet for this article.
May 12, 2017: Cancer
journal
journal
20067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"